title: The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study.
abstract: Metformin was found to affect plasma levels of some pituitary hormones. This study was aimed at investigating whether metformin treatment has an impact on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance. The study included 27 patients with hyperprolactinaemia, who had been treated for at least 6 months with bromocriptine. Based on prolactin levels, bromocriptine-treated patients were divided into two groups: patients with elevated (group A, n = 12) and patients with normal (group B, n = 15) prolactin levels. The control group included 16 age-, sex- and weight-matched hyperprolactinaemia-free individuals with impaired glucose tolerance (group C).The lipid profile, fasting plasma glucose levels, the homeostatic model assessment of insulin resistance ratio (HOMA-IR), glycated haemoglobin, as well as plasma levels of prolactin, thyrotropin and insulin-like growth factor-1 (IGF-1) were assessed at baseline and after 4 months of metformin treatment (2.55-3 g daily). In all treatment groups, metformin reduced HOMA-IR, plasma triglycerides and 2-h postchallenge plasma glucose. In patients with hyperprolactinaemia, but not in the other groups of patients, metformin slightly reduced plasma levels of prolactin, and this effect correlated weakly with the metabolic effects of this drug. Our study shows that metformin decreases plasma prolactin levels only in patients with elevated levels of this hormone. The obtained results suggest that metformin treatment may bring some benefits to hyperprolactinaemic patients with coexisting glucose metabolism disturbances already receiving dopamine agonist therapy.
authors.affiliation: Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, 40-752, Katowice, Poland, r.krysiak@interia.pl.
authors.forename: Robert
authors.initials: R
authors.lastname: Krysiak
authors.forename: Joanna
authors.initials: J
authors.lastname: Okrzesik
authors.forename: Boguslaw
authors.initials: B
authors.lastname: Okopien
mesh_terms: D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage*; D018491:Dopamine Agonists / Q000008:administration & dosage*; D005260:Female; D018149:Glucose Intolerance / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood* / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D008687:Metformin / Q000008:administration & dosage / Q000494:pharmacology*; D010865:Pilot Projects; D011388:Prolactin / Q000097:blood*
chemical_list: D018491:Dopamine Agonists; D007004:Hypoglycemic Agents; D001971:Bromocriptine; D011388:Prolactin; D008687:Metformin